Revenues of $6.1 billion, Compared to Prior Year Revenues of $6.2 billion
Retail Comparable Same Store Prescriptions Increased 4.4 Percent - Comparable Same Store Acute Prescriptions, Excluding COVID Immunizations, Increased 8.0 Percent
Same Store Front-End Sales, Excluding Tobacco, Increased 2.7%
Net Loss per Share of $1.23, Compared to the Prior Year Net Loss per Share of $0.67
Adjusted Net Loss per Share of $0.14, Compared to the Prior Year Adjusted Net Income of $0.15 per Share
Adjusted EBITDA of $121.9 million, Compared to the Prior Year Adjusted EBITDA of $154.8 million, with Elixir growing 39% to $40.2 million from $28.9 million
Fiscal 2023 Adjusted EBITDA Outlook Lowered to $410 million to $440 million, and Adjusted Net Loss per Share to be between $2.18 and $1.78
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.